| Date | Title | Description |
| 16.04.2020 | STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer | STipe Therapeutics announced the appointment of seasoned industry experts: “Both Natalie and Richard are highly experienced industry executives who bring a wealth of international drug development and approval expertise to STipe,” said Dr C... |
| 01.10.2019 | Daily funding roundup - September 30th, 2019 | PathogenDx raised $7.5M; Digit landed $27.5M; Kenna Security closed $48M
PathogenDx: PathogenDx is a pathogen testing technology for cannabis, hemp, agriculture and food safety industries. PathogenDx has raised $7.5 million in Series B fund... |
| 30.09.2019 | Arix co-leads EUR 20 million Series A investment round in STipe Therapeutics | - |
| 30.09.2019 | STipe Therapeutics Raises €20M in Series A Financing | STipe Therapeutics, an Aarhus, Denmark-based biotechnology company, raised €20m in Series A financing.
The round was co-led by Novo Seeds, the company creation team of Novo Holdings, and Arix Bioscience plc, who were joined by Wellington Pa... |
| 30.09.2019 | STipe Therapeutics launches with EUR 20 million Series A financing | STipe Therapeutics, a company founded to exploit a novel approach to the stimulator of interferon genes (STING) Pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders, launched today with an EUR ... |
